Paratek Pharmaceuticals Inc

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Role: lead

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

Role: collaborator

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Role: lead

Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Role: lead

Microbiome Effect of Omadacycline on Healthy Volunteers

Role: collaborator

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

Role: collaborator

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Role: collaborator

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

Role: lead

Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Role: collaborator

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Role: lead

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Role: lead

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

Role: lead

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

Role: lead

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Role: lead

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Role: lead

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Role: lead

Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Role: lead